Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Roussaki-Schulze AV, Sinclair R, Bassukas ID, Thomas D, Neale A, Arora P, Caux F, Werth VP, Gourlay SG, Joly P; BELIEVE trial investigators.
Murrell DF, et al. Among authors: stavropoulos p.
Br J Dermatol. 2021 Oct;185(4):745-755. doi: 10.1111/bjd.20431. Epub 2021 Jun 15.
Br J Dermatol. 2021.
PMID: 33942286
Free PMC article.
Clinical Trial.